Friess Associates’s Pfizer PFE Stock Holding History

Friess Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-32,480	Closed	-$1.92M	–	110
2021 Q4	$1.92M	Buy	+32,480	New	+$1.61M	0.75%	67
2016 Q4	–	Sell	-411,060	Closed	-$13.2M	–	165
2016 Q3	$13.2M	Hold	411,060	–	–	1.28%	40
2016 Q2	$13.7M	Sell	411,060 -56,515	-12%	-$1.8M	1.4%	37
2016 Q1	$13.1M	Buy	467,575 +463,760	+12,156%	+$13.2M	1.32%	37
2015 Q4	$117K	Sell	3,815 -522,969	-99%	-$16.5M	0.01%	138
2015 Q3	$15.7M	Hold	526,784	–	–	1.46%	28
2015 Q2	$16.8M	Sell	526,784 -3,868	-0.7%	-$126K	1.4%	30
2015 Q1	$17.5M	Buy	530,652 +526,837	+13,810%	+$16.7M	1.42%	28
2014 Q4	$113K	Hold	3,815	–	–	0.01%	134
2014 Q3	$107K	Hold	3,815	–	–	0.01%	133
2014 Q2	$107K	Buy	3,815 +73	+2%	+$2.08K	0.01%	136
2014 Q1	$114K	Hold	3,742	–	–	0.01%	131
2013 Q4	$109K	Buy	3,742 +158	+4%	+$4.6K	0.01%	123
2013 Q3	$98K	Hold	3,584	–	–	0.01%	117
2013 Q2	$95K	Buy	+3,584	New	+$99K	0.01%	112

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Friess Associates's PFE Position: Q1 2022 in Review

Friess Associates sold out of Pfizer (PFE) in Q1 2022, closing a stake of 32,480 shares — an estimated $1.92M sold.

Friess Associates first reported a position in PFE in Q2 2013 and held it in 15 quarters. The position peaked at $17.5M in Q1 2015. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

Friess Associates reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
Friess Associates sold 32,480 Pfizer shares in Q1 2022, an estimated $1.92M.
Friess Associates first reported a position in Pfizer in Q2 2013 and held it in 15 quarters.
Friess Associates's Pfizer position peaked at $17.5M in Q1 2015.
3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Friess Associates's 13F filing for Q1 2022, filed 12 May 2022.